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Oral cancer affects people globally with an estimated 657,000 new cases and 330,000 deaths 
yearly. Macrophage migration inhibitory factor (Mif) is a gene that encodes for a cytokine 
involved in regulating cell-mediated immunity, immunoregulation, and inflammation. Previous 
research has demonstrated that global Mif inhibition results in reduced oral cancer development. 
This was associated with a decrease in the accumulation of myeloid cell populations in the oral 
tumor microenvironment. It is therefore important to elucidate the role of Mif expression by 
myeloid populations in the oral tumor microenvironment. We previously generated floxed Mif 
reporter mice (Mif Fl/Fl). Selective breeding between Mif Fl/Fl mice and Cre knock-in mice (which 
contains a nuclear localized cre recombinase targeted to the Lysozyme 2 gene locus) (LysMCre) 
was performed to produce mice with Mif deficiency in myeloid cells. Genotypic characterization 
for Mif Fl/Fl and LysMCre was performed by PCR of genomic DNA extracted from mouse ear 
tissue. Phenotypic characterization of myeloid Mif deficiency was performed through flow 
cytometric analysis on various myeloid cell populations. Selective breeding of the Mif Fl/Fl mice 
with the LysMCre mice for three generations yielded myeloid-specific Mif deficient mice. 
Genotypic PCR characterization of Mif Fl/Fl mice yielded expected band sizes of 404 bp while 
wild-type mice yielded an expected band size of 221 bp. Furthermore, genotypic characterization 
of LysMCre mice yielded an expected band size of 700 bp while wild-type mice yielded an 
expected band size of 350 bp. Phenotypic flow cytometric analysis of myeloid-specific Mif 
deficient mice revealed deletion of Mif in bone marrow-derived macrophages and peritoneal 
macrophages, but not in lymphoid cells. Our data indicate that selective breeding of LysMCre 
mice with our recently generated Mif Fl/Fl mice results in conditional Mif gene removal in 
myeloid cells in mice, which can help us gain a better understanding of the role Mif plays in the 
context of oral cancer and other inflammatory diseases. 
 
1. Introduction 
Macrophage migration inhibitory factor (Mif) encodes for a pro-inflammatory cytokine 
(MIF) involved in the innate immune system [1]. It has been observed that MIF downregulates 
p53, which in turn is linked to a pro-inflammatory and tumor-promoting response [2]. 
Furthermore, through the binding to the receptor CD74, MIF leads to the activation of the 
ERK1/ERK2 signaling pathway, which counteracts the effects of glucocorticoids by causing 
increased phospholipase 2 (PLA2), an up-regulator of inflammation [3,4]. Overall, Mif 
contributes to an increased inflammatory innate immune response.  
Previously, it has been shown that global deletion of the Mif gene in mice (global Mif KO 
mice) leads to lower incidence and severity of oral cancer [5]. Moreover, another finding was the 
inhibition of myeloid cell-derived tumor-promoting cells in the global Mif KO mice [5]. 
Therefore, it is hypothesized that a mouse model in which Mif is conditionally deleted in only 
myeloid-derived cells will define the role of Mif in these cells during oral squamous cell 
carcinoma as well as other inflammatory diseases.  
Nat L. Sternberg discovered the cre recombinase and loxP system through his hypothesis 
that the previously unexplained linearity of the P1 bacteriophage’s recombination map was 
caused by site-specific recombination [6]. This event was seen to be caused by cre recombinase, 
a site-specific recombinase expressed by P1 [6,7]. It causes recombination by forming a covalent 
link with a DNA sequence called the loxP site that flanks the targeted gene (commonly referred 
to as floxing a gene) [8]. Through the covalent link, cre is then able to excise or invert the gene, 
depending on the orientation of the loxP sites [8]. Cre is now used in a plethora of ways, the 
majority of which is to create targeted conditional knockouts of various genes [8]. This began 
when Brian Sauer, an accomplice of Sternberg, developed a mouse cell line expressing cre 
recombinase under the control of an inducible metallothionein promoter and, through the 
introduction of DNA fragments containing loxP sites, demonstrated that cre loxP mediated 
recombination can be achieved in an in vivo murine model [9]. In order to create these models, 
cre is inserted into the genome under the control of a promoter specific to the targeted tissue or 
cell type for deletion, and the resulting mouse is crossbred with a mouse with the floxed gene 
intended for removal [8]. The final mice will express both cre recombinase and the floxed gene 
as well as demonstrate the cre loxP mediated recombination of the targeted gene [8]. 
LysMCre mice, a knock-in mouse model that expresses cre recombinase under the control 
of the myeloid cell-specific lysozyme 2 gene, developed by Clausen et al., is commonly used to 
generate myeloid-derived cell-specific conditional knockout mice [1010]. In previous literature, 
LysMCre mice have been used to develop a mouse model that demonstrates reduction of tumor 
development with myeloid cell-specific deletion of inositol-requiring enzyme 1 alpha in 
hepatocarcinoma [11]. Another of many examples of mouse models LysMCre mice were used in 
was to show how targeted macrophage downregulation of microsomal prostaglandin E2 
synthase-1 can possibly be used as a way to treat and prevent cardiovascular inflammatory 
diseases [12]. All in all, the LysMCre mouse model allows for the creation of myeloid cell-
specific targeted gene deleted mouse models that can be used in a wide variety of investigations. 
Therefore, through the use of the LysMCre mouse with a mouse expressing the floxed 
Mif gene, myeloid-specific Mif deficient mice can be generated for future investigation of its 
effects on oral carcinoma. 
 
2. Methods 
2.1. Mouse Handling 
 
C57BL/6 mice that were genetically modified to express the floxed Mif gene (Mif Fl/Fl) was 
generated previously by Dr. Oghumu.  C57BL/6 mice with a targeted mutation to express Cre 
recombinase within exon 1 of the lysozyme 2 gene [10] (LysMCre) were purchased from Jackson 
laboratory (JAX stock #004781). All mice were maintained in a 12 h day/night cycle, free access 
to food and water, and a temperature range held between 20-24 °C as well as a humidity range 
kept between 40-60%. These mice were monitored under the regulations upheld by the 
University Laboratory Animal Resources, which was approved by the Institutional Animal Care 
and Use Committee (Protocol #2018A00000054) as well as the Institutional Biosafety 
Committee of The Ohio State University.  
 
2.2. Generation of Myeloid-Specific Mif Deficient Mice 
 
The Mif Fl/Fl mice were bred with the LysMCre mice to generate the first filial generation (F1) 
Mif Fl/+ LysMCre +/- heterozygous mice (Figure 1A). These heterozygous mice were bred 
together to derive F2 Mif Fl/Fl LysMCre +/- mice, which are the myeloid-specific Mif deficient 
mice (Figure 1B). From these F2 progeny mice, breeder pairs were selected with genotypes Mif 
Fl/Fl LysMCre +/- and Mif Fl/Fl LysMCre -/- mice. Offspring from this final breeder pair produced 
were myeloid-specific Mif deficient and wild-type mice at a 1:1 ratio. 
(Figure 1) 
 
2.3. Polymerase Chain Reaction and Agarose Gel Analysis 
 
DNA was isolated from ear samples of the mice. Briefly, ear tissue was digested with 
Proteinase K, 20 mg/mL, (ThermoFisher Scientific) in SNET buffer. The DNA was isolated by 
an extraction through the use of 25:24:1 phenol: chloroform: isoamyl alcohol. Isopropanol then 
allowed for the precipitation of the DNA from its solubilized form, which was then isolated 
through centrifugation, washed with 70% ethanol, and reconstituted in TE buffer for future use. 
When using the Polymerase Chain Reaction (PCR) to genotype the floxed Mif gene, the Mif 
Fl/Fl primer set was used for detecting the floxed gene (Table 1, Figure 2B) which provided an 
expected band size at 404bp for the mutant gene (Table 1, Figure 2B). For the wild-type Mif 
gene, the Mif WT primer set was used, which provided a band of 221bp (Table 1, Figure 2B). 
For PCR genotyping of LysMCre, the presence of Cre recombinase was detected using the 
LysMCre Mut primer set, which gave a band of 700bp as well as the Cre recombinase primer set, 
which provide a band of 100 bp (Table 1, Figure 2A). Lastly, the primer set used for detecting 
the wild-type Lyz gene used was LysMCre WT, which provided a 350bp band (Table 1, Figure 
2A). All Cre primers were developed by The Jackson Laboratory [10] and Mif primers were 
developed previously by Dr. Oghumu. All Polymerase Chain Reactions were done using the 
OneTaq® Quick-Load® 2X Master Mix with Standard Buffer (New England Biolabs). The 
LysMCre and Mif PCR cycle conditions used in genotyping are shown in Table 2 and 3, 
respectively. DNA samples were run with 6X TriTrack DNA Loading Dye (Thermo Scientific) 
and GeneRuler 50 bp DNA Ladder, ready to use (Thermo Scientific) was used for determining 
band sizes. Furthermore, for all Mif genotyping, 2% agarose gels were used, and, for LysMCre 
genotyping, 1.5% agarose gels were used. Ethidium bromide and a UV transilluminator were 
used to image the agarose gels. 
 
Table 1. Primers used for genotypic characterization 
 
LysMCre Genotyping PCR Conditions 
Step Temp °C Time (min:sec) Notes 
1 94 2:00   
2 94 0:20   
3 65 0:15 -0.5 °C decrease per cycle  
4 68 0:20   
5 -- -- Repeat steps 2-4 for 10 cycles (Touchdown Protocol) 
Primer Set  Primer Name Sequence (5'-3') Expected Results (bp) 
Mif Flox 
Mif Common FW GTTCCACCTTCGCTTGAGTC 
404 
Mif flox RV CTGCAAAGGGTCGCTACAG 
Mif WT 
Mif Common FW GTTCCACCTTCGCTTGAGTC 
221 
Mif WT RV AGAGCCTGGGCTTCCATT 
LysMCre Mut 
LysMCre Common FW CTTGGGCTGCCAGAATTTCTC 
700 
LysMCre Mut RV CCCAGAAATGCCAGATTACG 
LysMCre WT 
LysMCre Common FW CTTGGGCTGCCAGAATTTCTC 
350 
LysMCre WT RV TTACAGTCGGCCAGGCTGAC 
6 94 0:15   
7 60 0:15   
8 68 0:45   
9 -- -- Repeat steps 6-8 for 28 cycles 
10 68 5:00   
11 10 --  
Table 2. PCR conditions used for genotypic characterization of LysMCre 
 
Mif Genotyping PCR Conditions 
Step Temp °C Time (min:sec) Notes 
1 94 3:00   
2 94 0:40   
3 47 0:40   
4 68 0:40   
5 -- -- Repeat steps 2-4 for 29 cycles 
6 68 5:00   
7 10 --  
Table 3. PCR conditions used for genotypic characterization of Mif 
 
2.4. Flow Cytometric Analysis 
 
Postmortem, we harvested the following organs or cell samples from the mice: spleens, 
lymph nodes, thioglycollate-elicited peritoneal macrophages and bone marrow. Collected spleens 
and lymph nodes were passed through a 70 µm nylon mesh, generating a single cell suspension 
of these organ samples. Splenocytes were treated for 3 min with ACK Lysis Buffer to lyse 
erythrocytes before further use. To stimulate thioglycollate-elicited peritoneal macrophages, 
mice targeted for sacrifice were given 1 mL intraperitoneal injections of 3.8% brewer’s 
thioglycollate made from Thioglycollate Broth (Sigma-Aldrich, St. Louis, MO, USA) 3 days 
prior to terminal sacrifice. Once the mice were euthanized, 5 mL of cold PBS was injected 
peritoneally to wash the cavity and then collected in order to extract the thioglycollate-elicited 
peritoneal macrophages. Lastly, bone marrow was extracted from the femurs and tibias of the 
mice and the erythrocytes within those samples were also lysed with ACK Lysis Buffer for 3 
minutes. They were then seeded on 24-well plates with media supplemented with 15% 
granulocyte macrophage colony stimulating factor (GM-CSF) or colony stimulating factor 1 
(CSF-1), which gave rise to bone marrow-derived dendritic cells and macrophages, respectively. 
3 days post, the cells were supplemented with an additional 75 µL of 15% GM-CSF or CSF-1 
treated media. 5-7 days post initial plating, these cells were scraped for analysis. 106 cells from 
each organ sample were incubated with 1 µg/mL CD11b or CD4 PE anti-mouse conjugated 
monoclonal antibodies (BD Pharmingen). Furthermore, the cells were permeabilized using 
intracellular staining permeabilization wash buffer and stained intracellularly with 0.2 µg/mL 
Rabbit anti-MIF primary antibodies (Invitrogen by Thermo Fisher Scientific, Waltham, MA, 
USA) diluted followed by AF647 conjugated goat anti-rabbit IgG secondary antibodies at a 
concentration of 1 µg/mL. The flow cytometric data was analyzed through FlowJo (Tree Star 
Inc., Ashland, OR, USA).  
 
3. Results 
3.1 Breeding Scheme 
 
In order to generate myeloid-specific Mif deficient mice, mice homozygous for the loxP 
flanked Mif gene (Mif FL/FL) were bred with mice homozygous for Cre recombinase within the 
lysozyme 2 gene or LysMCre+/+ (Figure 1A). The resulting pups that were all heterozygous for 
both floxed Mif and LysMCre were then crossbred (Figure 1B). The resulting progeny 
determined to be homozygous for floxed Mif and heterozygous for LysMCre were 7.89 % (3/38) 
of the total mice produced. These were the myeloid-specific Mif deficient mice. Mice 
homozygous for floxed Mif and wild-type for the Lyz gene were 13.16% (5/38) of the total mice 
produced. These were used as wild-type controls (Figure 1C). 
 
Figure 1. Breeding strategy used to generate Myeloid-specific Mif KO mice. (A) P1, the parental 
generation. (B) F1, the first filial generation. (C) F2, the second filial generation. 
 
Generation Genotype Frequency Percentage Expected Percentage 
F1 Mif Fl/+ Cre +/- 15/15  100 100 
F2 
Mif Fl/Fl Cre +/- 3/38 7.89 12.5 
Mif Fl/Fl Cre -/- 5/38 13.16 6.3 
Mif Fl/+ Cre +/- 12/38 31.58 25 
Mif +/+ Cre +/- 4/38 10.53 12.5 
Mif Fl/+ Cre +/+ 2/38 5.26 12.5 
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Mif Fl/+ Cre -/- 4/38 10.53 12.5 
Mif Fl/Fl Cre +/+ 0/38 0 6.3 
Mif +/+ Cre +/+ 6/38 15.79 6.3 
Mif +/+ Cre -/- 2/38 5.26 6.3 
Table 4. Frequencies, percentages, and expected percentages of all of the genotypes from the F1 
and F2 generations.  
 
3.2 Optimization of Mif Fl/Fl Genotyping Protocol 
 
In order to ensure clear results in the genotyping of Mif Fl/Fl, the PCR protocol was optimized 
through the use of gradient PCR. In gradient PCR, the optimal temperature for any step can be 
found by running the same sample at various temperatures. The most critical step is the 
annealing of the primers, which can be optimized in order to reduce nonspecific binding. By 
running a range of annealing temperatures from 38 to 63°C on both the wild-type and mutant 
assays of Mif genotyping protocols, the ideal annealing temperature for both primer pairs was 
determined to be 47.4°C (Figure 5). 
 
Figure 2. (A) Gradient PCR optimization of Mif WT assay using a Mif +/+ DNA sample with the 
annealing temperature range of 38-63 °C. (B) Gradient PCR optimization of Mif Mutant assay using a Mif 
fl/fl DNA sample with the annealing temperature range of 38-63 °C.  
 
3.3 Genotypic Characterization of LysMCre 
 
Throughout the selective breeding process, genotypic characterization by PCR and agarose 
gel electrophoresis was used to determine the mice selected for subsequent breeding, as 
described in the breeding scheme. For detecting the presence of Cre in the Lyz gene, two primer 
sets were used. The LysMCre Mut primer set, comprised of LysMCre Common FW and 
LysMCre Mut RV, provided a band of 700 bp to demonstrate the presence of Cre (Figure 2A). 
Secondly, the LysMCre WT primer set, containing LysMCre Common FW and LysMCre WT 
RV, showed a DNA band size of 350 bp, which was used to indicate the wild-type Lyz gene 
(Figure 2A). Throughout the selective breeding process, three different LysMCre genotypes were 
possible. First, LysMCre +/+ mice, which express LysMCre in both alleles of the Lyz gene, 












showed bands with only the LysMCre Mut primer set (Figure 3). LysMCre -/- mice or mice wild-
type for the Lyz gene display bands with only the LysMCre WT primer set (Figure 3). Lastly, 
LysMCre +/- mice who only express LysMCre in one allele of the Lyz gene exhibit bands with 
both LysMCre Mut and LysMCre WT primer sets (Figure 3).  
 
 
3.4 Genotypic Characterization of Mif Fl/Fl 
 
Similar to the genotyping of LysMCre, the detection of the loxP sequences flanking the Mif 
gene was done with two primer sets. Comprised of Mif Common FW and Mif Flox RV, the Mif 
Flox primer set provided a band size of 404 bp in the presence of the floxed Mif gene (Figure 
2B). On the other hand, the Mif WT primer set, which contains Mif Common FW and Mif WT 
RV, gave a band size of 221 bp in the presence of the wild-type Mif gene (Figure 2B). Analogous 
to the LysMCre genotyping, three different genotypes of the Mif gene were obtainable 
throughout the breeding experiment. Mice homozygous for floxed Mif, or Mif Fl/Fl, displayed 
bands only through the use of the Mif Flox primer set (Figure 4). Mif  Fl/+ mice that expressed the 
loxP sites in only one allele of the Mif gene showed bands with both the Mif WT and Mif Flox 
primer sets (Figure 4). Finally, Mif +/+ mice wild-type for the Mif gene expressed DNA bands 
only with the Mif WT primer set (Figure 4).  
 
Figure 3. (A) Gene map for LysMCre and Lyz WT locus and location of primers used for genotyping 























































Figure 4. LysMCre genotyping examples with LysMCre mouse, WT mouse, and heterozygous mouse 
DNA samples in both the WT and mutant assays. 
LysMCre +/+ LysMCre -/- LysMCre +/- Cre+8 STAT4KO9
WT Assay Mutant Assay





Figure 5. Mif genotyping examples with Mif fl/fl, Mif fl/+, and Mif +/+ mouse DNA samples in both the 
WT and mutant Assays. 
 
3.5 Phenotypic Characterization 
 
Flow cytometric analysis was used to visualize phenotypic differences in the expression of 
Mif in bone marrow-derived cells. The three types of mice that were investigated phenotypically 
were the myeloid-specific Mif deficient mice, Mif wild-type mice, and global Mif knockout mice. 
The CD11b expressing bone marrow-derived macrophages (BMDMS) as well as the CD11b 
expressing bone marrow-derived dendritic cells (BMDCs) both saw a decrease in Mif expression 
in the myeloid-specific Mif deficient mice as compared to the Mif wild-type mice (Figure 6). The 
CD11b expressing BMDCs however had a smaller decrease in Mif as compared to the BMDMs, 








WT Assay Mutant Assay
Mif Fl/+ Mif +/+ Mif fl/fl Mif fl/+ Mif +/+Ladder Ladder
404 bp
221 bp
Figure 6. (A) Flow cytometric analysis of bone marrow-derived macrophages. (B) Flow cytometric 
analysis of bone marrow-derived dendritic cells 
 
Thioglycollate-elicited peritoneal macrophages (PMs), lymph node-derived cells (LNs), 
and splenocytes (SPs) were all other various organs also phenotypically analyzed for differences 
in Mif expression. Similar to the BMDCs, the CD11b expressing PMs from the myeloid-specific 
Mif deficient mice had a slight decrease in Mif expression, but not to the level of the global Mif 
knockout (Figure 7A). In order to demonstrate the decreased Mif expression is myeloid cell-
specific, the Mif expression in the CD4 expressing populations in the LNs and SPs were 
compared across the same sample group. We determined, no notable difference in those 
populations between the myeloid-specific Mif deficient mice and the Mif wild-type mice (Figure 
7B and 7C). Furthermore, the global Mif knockout maintained decreased levels of expression 
across all populations (Figures 6 and 7). 
(A)
Mif WT Control
Mif Fl/Fl LysMCre+/- Myeloid KO
Mif Global KO Control
Mif WT Control Myeloid-Specific Mif 
Deficient Mouse
Mif Global KO Control
(B)
Mif WT Control Myeloid-Specific Mif 
Deficient Mouse
Mif Global KO Control
Mif WT Control
Mif Fl/Fl LysMCre+/- Myeloid KO
Mif Global KO Control
Figure 7. (A) Flow cytometric analysis of thioglycollate-elicited peritoneal macrophages. (B) Flow 




Here, we demonstrate the creation of myeloid-specific Mif deficient mice. This was 
achieved through the crossbreeding of a knock-in mouse expressing cre recombinase under the 
control of the Lysozyme 2 promoter and a mouse expressing the floxed Mif gene. Genotypic and 
phenotypic analysis with PCR and agarose gel electrophoresis as well as flow cytometry, 
respectively, were used to confirm the findings. With the creation of these mice, further studies 
can be undertaken to explore the effects of Mif deletion on oral carcinoma as well as in other 
inflammatory diseases.  
(A)
(B) Mif WT Control Myeloid-Specific Mif Deficient Mouse Mif Global KO Control
Mif WT Control
Mif Global KO Control
Mif WT Control Myeloid-Specific Mif 
Deficient Mouse
Mif Global KO Control
Mif WT Control
Mif Fl/Fl LysMCre+/- Myeloid KO
Mif Global KO Control
(C) Mif WT Control Myeloid-Specific Mif Deficient Mouse Mif Global KO Control
Mif Fl/Fl LysMCre+/- Myeloid KO
Mif Fl/Fl LysMCre+/- Myeloid KO
Mif WT Control
Mif Global KO Control
Previously, LysMCre mice have been used in a plethora of studies to examine the effects 
of the deletion of various genes in myeloid cells. An investigation on the effects of the Slc2a1 
myeloid-specific deletion as well as a study on the effects of ARTD1 myeloid-specific deletion 
both showed the use of BMDMs and PMs as a way to demonstrate the deletion of the genes as 
well as their effects [13,14]. Various other publications used other methods of confirming the cre 
mediated deletion of their genes as well. Western blotting and cell specific genotyping was 
another tactic to demonstrate gene deletion employed by Takeda et al. when investigating STAT3 
deletion in myeloid cells and its effect on enterocolitis [15]. It has been seen that the LysMCre 
mice have been used in a wide range of studies demonstrating its capabilities to create a myeloid 
specific targeted gene knockout mouse model.  
In the breeding scheme of the mice, although the myeloid-specific Mif knockout mouse 
was achieved, an improved scheme can be proposed. Other studies have used the strategy of 
backcrossing the heterozygous flox and heterozygous cre mice in the first filial generation with 
the homozygous flox parent mouse to achieve a higher chance of getting the desired mouse [16]. 
Although this change is not necessary for the creation of these mice, it can be made in future 
studies to expedite the creation of future mouse models. 
In the genotypic characterization of the mice, the optimization of the Mif Fl/Fl genotyping 
protocol allowed for clear results. It can be observed in figures 3 and 4 with each possible 
genotype shown that with these improvements, the genotypes of the mice were easily obtained 
and confirmed. 
In the phenotypic characterization, the reduction in Mif expression was tested through 
various organs and by isolating CD11b and CD4 expressing population as an example of 
myeloid cell populations and non-myeloid cell populations, respectively. The decrease in Mif 
expression can be seen in the CD11b expressing populations from the BMDMs, BMDCs, and 
PMs. This confirmed the excision of Mif through cre recombinase. Furthermore, this change in 
Mif expression was not seen in the CD4 expressing populations of the splenocytes and lymph 
node-derived cells. An interesting finding from this analysis was the lack of complete deletion of 
Mif in certain myeloid cell populations, as depicted in figures 6B and 7A. Although there was a 
reduction in Mif, there were still populations of CD11b cells that were expressing Mif in the 
BMDC and PM populations. This lack of entire deletion of Mif is analogous with other studies 
using the LysMCre model as well. Takeda et al. observed a residual expression of STAT3 
following LysMCre mediated deletion in the cell-specific PCR and western blotting of their PMs 
[15]. As observed through southern blotting by the team that developed the LysMCre mice, 
LysMCre is able to achieve 79% deletion in BMDMs and 31% in BMDCs, which explains the 
lack of entire deletion in our data as well [10]. Furthermore, our observations could also mean 
that there are certain CD11b cells that do not express the Lysozyme 2 gene and still express Mif, 
which could be investigated in future studies. Overall, the phenotypic characterization of the 
mice demonstrated and confirmed the myeloid cell-specific deletion of Mif.  
Through the use of genotypic characterization, mice resulting from the crossbreeding of 
the LysMCre and Mif Fl/Fl mice were able to be identified and the myeloid-specific Mif deficient 
mice were able to be selected out. With the optimization of the Mif Fl/Fl genotyping protocol, the 
identification of these mice was improved and made clearer for the team. Using flow cytometric 
analysis of CD11b populations in BMDMs, BMDCs, and PMs as well as CD4 populations in 
LNs and SPs; the myeloid-specific Mif deficient mice were phenotypically characterized to 
demonstrate cre mediated decreased levels of Mif in only myeloid cells. Through the creation of 
this mouse model, the role of Mif deletion during oral cancer and other inflammatory diseases 
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